[1] |
Fujisawa T, Hozumi H, Kono M, et al. Predictive factors for long⁃term outcome in polymyositis/dermatomyositis⁃associated inter⁃stitial lung diseases[J]. Respir Investig, 2017,55(2):130⁃137. doi: 10.1016/j.resinv.2016.09.006.
|
[2] |
Muro Y, Sugiura K, Akiyama M. Cutaneous manifestations in dermatomyositis: key clinical and serological features⁃a comprehensive review[J]. Clin Rev Allergy Immunol, 2016,51(3):293⁃302. doi: 10.1007/s12016⁃015⁃8496⁃5.
|
[3] |
Sasaki Y, Okuyama R, Tsunoda T, et al. Keratotic palmar papules in a dermatomyositis patient preceding the development of inter⁃stitial pneumonia[J]. Dermatology, 2007,215(2):169⁃170. doi: 10.1159/000104272.
|
[4] |
Koguchi⁃Yoshioka H, Okiyama N, Iwamoto K, et al. Intravenous immunoglobulin contributes to the control of antimelanoma differentiation⁃associated protein 5 antibody⁃associated dermato⁃myositis with palmar violaceous macules/papules[J]. Br J Dermatol, 2017,177(5):1442⁃1446. doi: 10.1111/bjd.15499.
|
[5] |
Mainetti C, Terziroli BB, Selmi C. Cutaneous manifestations of dermatomyositis: a comprehensive review[J]. Clin Rev Allergy Immunol, 2017,53(3):337⁃356. doi: 10.1007/s12016⁃017⁃8652⁃1.
|
[6] |
Sontheimer RD. MDA5 autoantibody⁃another indicator of clinical diversity in dermatomyositis[J]. Ann Transl Med, 2017,5(7):160. doi: 10.21037/atm.2017.03.94.
|
[7] |
Dandelooy J, van Hal PT, Even P, et al. Not just ordinary hand dermatitis: mechanic′s hands revealing dermatomyositis[J]. J Eur Acad Dermatol Venereol, 2016,30(7):1223⁃1224. doi: 10.1111/jdv.13149.
|
[8] |
毛秋霞, 李文锐, 赵思佳, 等. 伴反向Gottron丘疹的皮肌炎三例[J]. 中华皮肤科杂志, 2017,50(12):875⁃878. doi: 10.3760/cma.j.issn.0412-4030.2017.12.004.
|
[9] |
Sontheimer RD. Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis siné myositis) as a distinctive subset within the idiopathic inflammatory dermato⁃myopathies spectrum of clinical illness?[J]. J Am Acad Dermatol, 2002,46(4):626⁃636.
|
[10] |
Li L, Wang Q, Yang F, et al. Anti⁃MDA5 antibody as a potential diagnostic and prognostic biomarker in patients with dermato⁃myositis[J]. Oncotarget, 2017,8(16):26552⁃26564. doi: 10.18632/ oncotarget.15716.
|
[11] |
Fiorentino D, Chung L, Zwerner J, et al. The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM⁃140): a retrospective study[J]. J Am Acad Dermatol, 2011,65(1):25⁃34. doi: 10.1016/j.jaad.2010.09.016.
|
[12] |
Alsumrain M, De Giacomi F, Mirza S, et al. Utility of autoimmune serology testing in the assessment of uncharacterized interstitial lung disease: a large retrospective cohort review[J]. Respir Res, 2017,18(1):161. doi: 10.1186/s12931⁃017⁃0644⁃4.
|
[13] |
Kobayashi N, Takezaki S, Kobayashi I, et al. Clinical and laboratory features of fatal rapidly progressive interstitial lung disease associated with juvenile dermatomyositis[J]. Rheumatology (Oxford), 2015,54(5):784⁃791. doi: 10.1093/rheumatology/keu385.
|